title: Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice.
abstract: BACKGROUND
  Passive immunization for the treatment of Alzheimer's disease (AD) was rapidly translated into clinical trials. However, basic mechanisms of AD immunotherapy remain only partially understood.
  
  
  METHODS
  We analyzed the dynamic changes of amyloid-β (Aβ) levels in plasma, brain, and cerebrospinal fluid (CSF) as well as cerebral amyloid binding by Aβ antibody after a single β1-antibody infusion into APP(Swedish) and APP(wildtype) transgenic mice at preplaque and plaque-bearing age.
  
  
  RESULTS
  Following intravenous Aβ antibody treatment, plasma Aβ increased rapidly, reaching significantly higher levels in preplaque compared with plaque-bearing mice, whereas cerebral and CSF Aβ remained unchanged. Strikingly, Aβ antibodies exhibited strong cerebral amyloid plaque binding rapidly after intravenous administration in a subset of animals with more severe vascular amyloid.
  
  
  CONCLUSIONS
  Rapid plasma Aβ increase after Aβ antibody infusion results primarily from stabilization of Aβ. Nevertheless, the smaller plasma Aβ increase in plaque-bearing mice might be of diagnostic use. Importantly, intravenously administered antibodies can rapidly bind to cerebral plaques, potentially facilitated by vascular-amyloid-mediated damage of the blood-brain barrier.
authors.affiliation: Department of Neurology, University Hospital Basel, Basel, Switzerland. winklerd@uhbs.ch
authors.forename: David T
authors.initials: DT
authors.lastname: Winkler
authors.forename: Dorothee
authors.initials: D
authors.lastname: Abramowski
authors.forename: Simone
authors.initials: S
authors.lastname: Danner
authors.forename: Mauro
authors.initials: M
authors.lastname: Zurini
authors.forename: Paolo
authors.initials: P
authors.lastname: Paganetti
authors.forename: Markus
authors.initials: M
authors.lastname: Tolnay
authors.forename: Matthias
authors.initials: M
authors.lastname: Staufenbiel
mesh_terms: D000367:Age Factors; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid / Q000276:immunology* / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D001921:Brain / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000276:immunology*; D007262:Infusions, Intravenous; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D058225:Plaque, Amyloid / Q000276:immunology / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D007074:Immunoglobulin G